NCT04032782View on ClinicalTrials.gov

A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

August 29, 2019

Study Completion Date

August 29, 2019

Conditions
Pharmacology
Interventions
DRUG

HM15136

10 mg/mL as protein in prefilled syringes

DRUG

Placebo of HM15136

Placebo in prefilled syringes

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04032782 - A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects | Biotech Hunter | Biotech Hunter